Report Considers When Researchers Should Share Results with Participants
Policy and Advocacy News
National Academies Panel Urges Researchers to Routinely Share Test Results with Study Participants
July 10, 2018 | STAT
A National Academies report encourages researchers to consider sharing data with study participants and recommends revisions to related federal regulations. Specifically, the Panel would like for the Centers for Medicare and Medicaid Services to permit results to be returned under institutional review board oversight when participants request access to their data.
- Join the Advocacy Network to stay informed about issues related to neuroscience research at SfN.org
Leaky Pipeline For Women Dries Up After They Win Their First Grant
July 18, 2018 | Nature
An analysis of 35,000 biomedical researchers indicates that the attrition of women in science occurs prior to their first NIH grant but that women receive grants at a similar rate as males for the rest of their careers.
- Learn about science funding resources at SfN.org
Scientific Procedures Involving Animals at Lowest Level Since 2010
July 19, 2018 | The Guardian
The UK Home Office reports a 4% decline in experiments involving vertebrates over the last year and the lowest level since 2010.
- Read about global advocacy programs at SfN.org
What's the Way Forward to Reform Graduate Training?
July 11, 2018 | Science
This editorial criticizes the latest National Academies report on graduate studies for not providing recommendations regarding graduate education reform. The piece, however, commends the National Academies for emphasizing the mismatch in incentives between faculty hiring graduate students for lab work and graduate students’ career prospects.
- Engage in U.S. advocacy programs at SfN.org
Articles of Interest
Potential DNA Damage From CRISPR Has Been “Seriously Underestimated,” Study Finds
July 16, 2018 | STAT
A new study indicates CRISPR cuts DNA in a far more destructive way than once thought, potentially deleting or rearranging thousands of DNA bases.
- Learn more about CRISPR and genetic editing at BrainFacts.org
Questions Raised About Breakthrough Therapies’ Clinical Support
July 17, 2018 | The Scientist
A recent report found that drugs with “breakthrough therapy” designations were approved with weaker clinical evidence, casting doubt on the modified drug approval process. The breakthrough status is intended to speed up the review of therapies especially for conditions without treatments currently available.
- Find SfN’s policy positions at SfN.org